

Stratifying rate of disease progression by progression likelihood scores in children and adolescents with stage 1 and stage 2 type 1 diabetes in Germany

Andreas Weiss, MSc<sup>1,2</sup>; Lenche Chakievská, PhD<sup>1,2</sup>; Peter Achenbach, MD<sup>1,2,3</sup>; Maja Hergl, BSc<sup>1,2</sup>; Sandra Hummel, PhD<sup>1,2,3</sup>, Raffael Ott, PhD<sup>1,2</sup>; Marlon Scholz<sup>1,2</sup>; Christiane Winkler, PhD<sup>1,2</sup>; Ezio Bonifacio, PhD<sup>2,4,5</sup>; Anette-Gabriele Ziegler, MD<sup>1,2,3</sup>

<sup>1</sup> Institute of Diabetes Research, Helmholtz Munich, German Research Center for Environmental Health, Munich, Germany

<sup>2</sup> German Center for Diabetes Research (DZD), Munich, Germany.

<sup>3</sup> Technical University Munich, School of Medicine and Health, Forschergruppe Diabetes at Klinikum rechts der Isar, Munich, Germany


<sup>4</sup> Center for Regenerative Therapies Dresden, Faculty of Medicine, Technische Universität Dresden, Dresden, Germany

<sup>5</sup> Paul Langerhans Institute Dresden of the Helmholtz Munich at University Hospital Carl Gustav Carus and Faculty of Medicine, TU Dresden, Germany


**Online-only supplemental material**

## Table of Contents


Supplemental Figure 1 .....	3
Supplemental Figure 2 .....	4
Supplemental Figure 3 .....	5
Supplemental Figure 4 .....	6
Supplemental Figure 5 .....	7
Supplemental Figure 6 .....	8
Supplemental Figure 7 .....	9




**Supplemental Figure 1.** Fr1da early-stage type 1 diabetes cohort and follow-up outcomes.




**Supplemental Figure 2.** Stratification of progression from stage 1 to stage 3 type 1 diabetes by the progression likelihood score (PLS) calculated using IA-2A units measured by radiobinding assay (RBA, solid lines) and electrochemiluminescence (ECL, dashed lines) assay. Children were categorized using previously defined PLS thresholds as <0.5 (low, black line), 0.5 – 4.0 (intermediate, blue line) and >4.0 (high, red line). The IA-2A categories for the ECL assay were matched to the centiles of the RBA categories and corresponded to 6.5 units (negative), >6.5 – 82 units, >82 – 1250 units, and >1250 units. Progression differed significantly among categories in both the PLS derived from the ECL IA-2A units ( $p<0.0001$ ) and the RBA IA-2A units ( $p=0.0001$ ). The numbers underneath the x axis indicate the number remaining at each year of follow-up.




**Supplemental Figure 3.** Association of demographic, autoantibody and metabolic variables with progression rate to stage 3 type 1 diabetes. Shown are the hazard ratios (black squares) and the 95% confidence intervals (lines) from univariable Cox proportional hazards models analyzing progression to stage 3 type 1 diabetes in the 360 children with stage 1 in the Fr1da cohort. The variables age, OGTT glucose values at 0, 30, 60, 90, 120 minutes, HbA1c and BMI z-score were continuous variables. The remainder were categorical and expressed as a hazard ratio against the relative reference comparator. \*Numbers for continuous variables represent the numbers with information; numbers (%) for categorical variables represent the number and frequency in the category.




**Supplemental Figure 4.** Stratification of progression from stage 1 to stage 3 type 1 diabetes by the progression likelihood score (PLS) and obesity in children in the Fr1da cohort. Kaplan-Meier survival curves for progression to stage 3 in A) children with a low PLS ( $p=0.83$ ), B) intermediate PLS ( $p=0.007$ ), C) high PLS ( $p=0.017$ ) for children who are obese (red lines) and not obese (blue lines). The numbers underneath the x axis indicate the number remaining at each year of follow-up.



**Supplemental Figure 5.** Receiver operator characteristic (ROC) curve for non-OGTT based progression score for its ability to discriminate the Fr1da cohort children with stage 1 who developed stage 3 type 1 diabetes within 2 years of follow-up (sensitivity) from those who were followed for at least 2 years without developing stage 3 (1 – specificity). The vertical/horizontal dashed lines show the performance at the PLS thresholds of 1.25 (black) and 3 (red). The diagonal dashed line represents no discrimination.



**Supplemental Figure 6.** Sensitivity analysis of a non-OGTT-based progression score for stratification of progression from stage 1 to stage 3 type 1 diabetes. Stage 1 type 1 diabetes was classified on the basis of a normal HbA1c value without considering OGTT measurements. Kaplan-Meier survival curves for progression to stage 3 type 1 diabetes are shown for children with scores <1.25 (black line), 1.25 to 3.0 (blue line) and >3.0 (red line). Progression differed significantly among categories ( $p<0.0001$ ). The numbers underneath the x axis indicate the number remaining at each year of follow-up.



**Supplemental Figure 7.** Stratification of progression from stage 2 to stage 3 type 1 diabetes by the progression likelihood score (PLS) in children who progressed to stage 2 during follow-up. Kaplan-Meier survival curves for progression to stage 3 type 1 diabetes in 133 children diagnosed with stage 2 type 1 diabetes in follow-up in the Fr1da cohort, having only one dysglycemic value. Children were categorized as those with a PLS  $\leq$  1.6 (n= 61, blue line) and those with a PLS  $>$  1.6 (n=72, red line). Progression differed significantly among categories ( $p<0.0001$ ). The numbers underneath the x axis indicate the number remaining at each year of follow-up.